AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 22 min read$IART

Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed an SEC Form 8-K — Results of Operations and Financial Condition. Integra LifeSciences Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance PRINCETON, N.J., October 2, 2026 – Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certa

Original reporting
SEC EDGAR 8-K
Published Oct 2, 2026, 12:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 12:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$IART
Bearish
high confidence
Mentioned
$IART
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IARTBearishMed
01

Why it matters

The guidance reduction reflects a $7 M Q3 revenue hit and a $15‑20 M Q4 hit, prompting likely downside pressure.

02

Market read

Guidance cut is a primary disclosure that can move IART and related med‑tech stocks.

03

What to watch

Potential insurance recoveries and a return to full manufacturing in Q2 2027 may mitigate the impact.

Relevance 7/10Novelty 8/10Timing: ahead of Q3 earnings release

Background

Integra LifeSciences disclosed preliminary Q3 2026 results and updated full‑year guidance after a July flood disrupted its Cincinnati facility.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Integra LifeSciences lowered its full‑year 2026 revenue and adjusted EPS outlook and provided preliminary Q3 results.

Expected impact

likely pressure as the market prices in the lowered guidance

Evidence & confidence

The 8‑K filing is the first disclosure of the revised revenue range ($1.634‑$1.654 B) and EPS range ($2.30‑$2.40), both below prior guidance, which typically triggers a sell‑off.

Market effects

Sector

Medical technology sector may see modest downside as a leading player trims outlook.

Regional

U.S. healthcare stocks could face slight pressure in the near term.

Global

Limited to investors tracking U.S. med‑tech earnings guidance.

Counterpoint

What could challenge this read

If cash flow remains strong and insurance recoveries offset losses, the stock could rebound.

Key entities

  • Executive
    Stuart Essig

    Chairman and CEO of Integra LifeSciences

Read at source← All news

Also covered by

5 outlets

Related articles

OCT 2
$IARTHighAI 8/10

Why is Integra LifeSciences stock tumbling today?

Integra LifeSciences (IART) shares fell 16.2% to $13.49 after lowering its 2026 revenue and EPS guidance due to flooding damage at a key facility. The company expects $7M in Q3 revenue loss and $15M-$20M in Q4. It also announced a $600M debt refinancing. The stock dropped despite a positive U.S. market day.

investing.com2 min
OCT 2
$IARTHighAI 8/10

Integra LifeSciences Cuts FY26 Guidance Following Cincinnati Facility Flooding; Stock Tumbles 11.4%

Integra LifeSciences (IART) cut its FY26 adjusted earnings and revenue guidance due to July flooding at its Cincinnati facility. Q3 adjusted earnings are expected between $0.55 and $0.59 per share on revenues of $410M-$412M. FY26 adjusted earnings are now projected at $2.30-$2.40 per share on revenues of $1.634B-$1.654B, down from previous guidance. The stock fell 11.44% in pre-market trading.

rttnews.com2 min
OCT 2
$IARTHigh

Integra LifeSciences cuts 2026 guidance after flooding impact

Integra LifeSciences (IART) lowered its 2026 guidance due to flooding at its Cincinnati facility, reducing revenue and EPS forecasts. Q3 revenue is expected at $410M-$412M, with full-year revenue now projected at $1.634B-$1.654B. The company estimates a $7M Q3 and $15M-$20M Q4 revenue impact. Full operations are expected to resume by Q2 2027, with insurance covering some losses. CEO Stuart Essig anticipates Q3 operating cash flow of over $85M and full-year cash flow of $190M-$200M.

investing.com2 min